Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 607,521 | 667,238 | 579,775 | 520,397 | 392,755 |
| Cost of Goods | 83,779 | 87,221 | 75,061 | 52,459 | 16,660 |
| Gross Profit | 523,742 | 580,017 | 504,714 | 467,938 | 376,095 |
| Operating Expenses | 529,790 | 534,114 | 418,746 | 294,699 | 228,184 |
| Operating Income | -5,269 | 46,124 | 86,029 | 173,698 | 148,571 |
| Interest Expense | 2,415 | 7,070 | 23,423 | 23,754 | 22,707 |
| Other Income | 10,453 | 21,689 | 10,569 | 18,704 | 21,623 |
| Pre-tax Income | 2,769 | 60,743 | 73,175 | 168,648 | 147,487 |
| Income Tax | 1,453 | 32 | 19,751 | 41,698 | 34,431 |
| Net Income Continuous | 1,316 | 60,711 | 53,424 | 126,950 | 113,056 |
| Net Income | $1,316 | $60,711 | $53,424 | $126,950 | $113,056 |
| EPS Basic Total Ops | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 |
| EPS Basic Continuous Ops | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 |
| EPS Diluted Total Ops | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
| EPS Diluted Continuous Ops | 0.02 | 0.98 | 0.98 | 2.36 | 2.10 |
| EPS Diluted Before Non-Recurring Items | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
| EBITDA(a) | $80,000 | $137,012 | $136,543 | $205,531 | $166,904 |